gdc
ImmunotherapyLymphoma

Keytruda Immunotherapy Prolongs Survival in Patients with Relapsed or Refractory Hodgkin Lymphoma

This article discusses findings from a clinical trial showing that Keytruda prolongs the time without disease progression in patients with relapsed or refractory classical Hodgkin lymphoma compared with the current standard of therapy.
August 2020 – Immunotherapy
Phoebe Starr

Using the immunotherapy Keytruda (pembrolizumab), a PD-1 inhibitor, prolongs the time without disease progression in patients with relapsed (coming back) or refractory (not responding to treatment) classical Hodgkin lymphoma compared with the current standard of therapy of Adcetris (brentuximab vedotin), an antibody–drug conjugate.

This information is based on results from a phase 3 clinical trial known as KEYNOTE-204, which were presented at the recent 2020 virtual annual meeting of the American Society of Clinical Oncology. The average time without disease progression in these patients was almost 5 months longer with Keytruda compared with Adcetris—13.2 months with Keytruda compared with 8.3 months with Adcetris.

This longer time without disease progression in those using Keytruda was seen in different groups of patients with classical Hodgkin lymphoma, including patients whose disease relapsed after autologous stem-cell transplant, or ASCT, patients who were not eligible for transplant, and patients who had never received Adcetris therapy.

“Based on these findings, pembrolizumab [Keytruda] should be considered the preferred treatment option and new standard of care for relapsed or refractory classical Hodgkin lymphoma in patients who have relapsed post-ASCT or are ineligible for ASCT,” said John Kuruvilla, MD, FRCPC, with Princess Margaret Cancer Centre in Toronto, Canada.

The current standard of care for patients with relapsed or refractory classical Hodgkin lymphoma is chemotherapy, a transplant, and Adcetris, which is also used as the first-line therapy for patients with this type of lymphoma.

Improved Survival

This study included 304 patients who were divided equally into 2 groups. One group received Keytruda immunotherapy and the other group received Adcetris. The average follow-up period was 24.7 months.

The results showed that Keytruda significantly improved the time without disease progression compared with Adcetris and reduced the risk for disease progression or death by 35%. Specifically, immunotherapy with Keytruda reduced the risk for disease progression or death by 39% in patients who did not have a transplant; by 48% in patients with refractory disease; by 66% in patients who had previously received Adcetris; and by 33% in patients who had not received Adcetris previously.

Among patients who had a response to therapy, the response lasted 20.7 months with Keytruda compared with 13.8 months with Adcetris.

Side Effects

Serious side effects (grade 3 or 4) related to the treatment were reported in 19.6% of the patients receiving immunotherapy and 25% with Adcetris. However, 1 death was reported in the immunotherapy group from serious pneumonia.

Immune-mediated side effects that are associated with immunotherapy were higher in the pembrolizumab group; the most common of these side effects were hypothyroidism (18.9%) and pneumonitis (10.8%).

Share this:

Recommended For You
Breast CancerImmunotherapyMetastatic Breast Cancer
Immunotherapy for the Management of Triple-Negative Metastatic Breast Cancer
By Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
You have been reading about various forms of management of your disease. Now let us discuss one of the newest forms of systemic treatment—immunotherapy. Sometimes immunotherapy is called biologic therapy, or biotherapy, because it uses the body’s own defense system to fight the breast cancer.
Bladder Cancer
Maintenance Treatment with Bavencio a New Standard of Care for Patients with Advanced Bladder Cancer
By Phoebe Starr
Interim analysis of the phase 3 JAVELIN Bladder 100 trial showed that maintenance therapy with the PD-L1 inhibitor Bavencio (avelumab) plus best supportive care significantly prolonged survival compared with the current best supportive care alone in patients with advanced urothelial carcinoma, the most common type of bladder cancer, that did not progress (get worse) after treatment with first-line platinum-based chemotherapy.
Last modified: October 16, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country